Trial Profile
A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naive and Previously Treated Subjects With Choroidal Neovascularisation (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Nov 2014
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Adverse reactions; Registrational
- Sponsors Genentech
- 15 Aug 2014 New trial record
- 15 Aug 2014 New trial record
- 28 Jan 2008